211 related articles for article (PubMed ID: 28365942)
1. Development, characterization and evaluation of doxorubicin nanostructured lipid carriers for prostate cancer.
Zhang HW; Dang Q; Zhang ZW; Wu FS
J BUON; 2017; 22(1):102-111. PubMed ID: 28365942
[TBL] [Abstract][Full Text] [Related]
2. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
Soni K; Rizwanullah M; Kohli K
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
[TBL] [Abstract][Full Text] [Related]
3. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
4. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?
Du J; Li L
Drug Deliv; 2016 Jun; 23(5):1799-809. PubMed ID: 26455787
[TBL] [Abstract][Full Text] [Related]
5. Nanostructured lipid carriers as a delivery system of biochanin A.
Wang Q; Cheng H; Zhou K; Wang L; Dong S; Wang D; Chen W
Drug Deliv; 2013 Nov; 20(8):331-7. PubMed ID: 24111887
[TBL] [Abstract][Full Text] [Related]
6. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
Lin C; Chen F; Ye T; Zhang L; Zhang W; Liu D; Xiong W; Yang X; Pan W
Int J Pharm; 2014 Apr; 465(1-2):90-6. PubMed ID: 24530388
[TBL] [Abstract][Full Text] [Related]
7. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
[TBL] [Abstract][Full Text] [Related]
8. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation.
Liu X; Zhang Z; Jiang Y; Hu Y; Wang Z; Liu J; Feng R; Zhang J; Huang G
Drug Deliv; 2015 Feb; 22(2):223-9. PubMed ID: 24559497
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
10. Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats.
Zhang S; Wang J; Pan J
Drug Deliv; 2016 Nov; 23(9):3696-3703. PubMed ID: 27749105
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
[TBL] [Abstract][Full Text] [Related]
12. Construction and in vitro/in vivo evaluation of 17-allylamino-17-demethoxygeldanamycin (17AAG)-loaded PEGylated nanostructured lipid carriers.
Wang Z; Wang J; Yang S; Hou S
Drug Dev Ind Pharm; 2016 Jan; 42(1):91-98. PubMed ID: 25853294
[TBL] [Abstract][Full Text] [Related]
13. Design and characterization of Amoitone B-loaded nanostructured lipid carriers for controlled drug release.
Luan J; Zhang D; Hao L; Li C; Qi L; Guo H; Liu X; Zhang Q
Drug Deliv; 2013 Nov; 20(8):324-30. PubMed ID: 24032657
[TBL] [Abstract][Full Text] [Related]
14. Long circulation nanostructured lipid carriers for gambogenic acid: formulation design, characterization, and pharmacokinetic.
Lin T; Huang X; Wang Y; Zhu T; Luo Q; Wang X; Zhou K; Cheng H; Peng D; Chen W
Xenobiotica; 2017 Sep; 47(9):793-799. PubMed ID: 27618478
[TBL] [Abstract][Full Text] [Related]
15. Targeted nanostructured lipid carrier containing galangin as a promising adjuvant for improving cytotoxic effects of chemotherapeutic agents.
Hajipour H; Nouri M; Ghorbani M; Bahramifar A; Emameh RZ; Taheri RA
Naunyn Schmiedebergs Arch Pharmacol; 2021 Dec; 394(12):2353-2362. PubMed ID: 34522984
[TBL] [Abstract][Full Text] [Related]
16. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Ranpise NS; Korabu SS; Ghodake VN
Colloids Surf B Biointerfaces; 2014 Apr; 116():81-7. PubMed ID: 24445002
[TBL] [Abstract][Full Text] [Related]
17. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin.
Han Y; Zhang Y; Li D; Chen Y; Sun J; Kong F
Int J Nanomedicine; 2014; 9():4107-16. PubMed ID: 25187713
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers.
Luan J; Zhang D; Hao L; Qi L; Liu X; Guo H; Li C; Guo Y; Li T; Zhang Q; Zhai G
Colloids Surf B Biointerfaces; 2014 Feb; 114():255-60. PubMed ID: 24211416
[TBL] [Abstract][Full Text] [Related]
19. Agranulocytosis-Protective Olanzapine-Loaded Nanostructured Lipid Carriers Engineered for CNS Delivery: Optimization and Hematological Toxicity Studies.
Gadhave DG; Tagalpallewar AA; Kokare CR
AAPS PharmSciTech; 2019 Jan; 20(1):22. PubMed ID: 30604305
[TBL] [Abstract][Full Text] [Related]
20. Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer.
Borges GSM; Silva JO; Fernandes RS; de Souza ÂM; Cassali GD; Yoshida MI; Leite EA; de Barros ALB; Ferreira LAM
Life Sci; 2019 Sep; 232():116678. PubMed ID: 31344429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
